Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Feb 27, 2020 (7 years ago)

Elelyso (taliglucerase alfa)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility--Reports of loose metal ferrule crimps on vials for injection. The entire cap either lifted or dislodged while attempting to flip off the orange color plastic button.

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Elelyso (taliglucerase alfa) for injection, 200 units/vials,, Rx only, Distributed by Pfizer Labs, Division of Pfizer Inc, NY, NY 10017. NDC 0069-0106-01

Affected NDC 0069-0106-01

Compare with the code on your package — it is the most precise check available.

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Elelyso
Taliglucerase alfa
NDC 00069-0106
200 U/5mL Injection, Powder, Lyophilized, for Solution
Intravenous
Pfizer Laboratories Div Pfizer Inc Rx
Recalling firm
Pfizer Inc.
NDC code
0069-0106-01
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0995-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by Pfizer Inc.

All 2020 recalls

Other sterility / contamination recalls from 2020

All sterility / contamination recalls
Class II · Moderate risk

Zerbaxa (ceftolozane and tazobactam)

Lack of assurance of sterility: The results of sterility tests of seven batches of product were out of specification. Five of these batches tested positive for Ralstonia pickettii and two batches produced turbid results that could not be further identified. While all product distributed to the market has met the registered specifications for release, including for sterility, it was manufactured on the same equipment as the affected batches.

Terminated Sterility / contamination Merck Sharp & Dohme NDC 67919-030-01 D-0176-2021